• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early or late administration of Nirmatrelvir/ritonavir in mild COVID-19 patients with clinical comorbidities: A propensity score-matched territory-wide study.

作者信息

Liu Shuang, Shen Xuan, Zhang Fen, Shi Xiaoqian, Li Bing, Xu Jinfang, Wang Congrong

机构信息

Department of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.

Department of Pulmonary and Critical Care Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.

出版信息

Travel Med Infect Dis. 2023 Nov-Dec;56:102656. doi: 10.1016/j.tmaid.2023.102656. Epub 2023 Oct 26.

DOI:10.1016/j.tmaid.2023.102656
PMID:37898259
Abstract
摘要

相似文献

1
Early or late administration of Nirmatrelvir/ritonavir in mild COVID-19 patients with clinical comorbidities: A propensity score-matched territory-wide study.轻度新冠肺炎合并临床并发症患者早期或晚期使用奈玛特韦/利托那韦：一项倾向评分匹配的全地区研究。
Travel Med Infect Dis. 2023 Nov-Dec;56:102656. doi: 10.1016/j.tmaid.2023.102656. Epub 2023 Oct 26.
2
Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.在养老院居住的患者中，使用奈玛特韦/利托那韦和莫努匹韦治疗 COVID-19 的临床结果。
JAMA Netw Open. 2023 Apr 3;6(4):e2310887. doi: 10.1001/jamanetworkopen.2023.10887.
3
Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.中国北京奥密克戎疫情期间，奈玛特韦-利托那韦治疗与住院 COVID-19 患者死亡和临床改善的关联：一项多中心、回顾性队列研究。
Ann Med. 2024 Dec;56(1):2313062. doi: 10.1080/07853890.2024.2313062. Epub 2024 Feb 14.
4
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.阿兹夫定、莫努匹韦和奈玛特韦/利托那韦在轻中度 COVID-19 成年患者中的比较：一项回顾性队列研究。
Sci Rep. 2024 Feb 9;14(1):3318. doi: 10.1038/s41598-024-53862-y.
5
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.奥密克戎变异株流行期间，未住院的 2 型糖尿病合并 SARS-CoV-2 感染患者接受莫努匹韦或奈玛特韦/利托那韦治疗后的全因住院和死亡分析。
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
6
Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.奈玛特韦/利托那韦或莫努匹韦治疗后 COVID-19 反弹的临床特征：一项前瞻性队列研究。
Medicine (Baltimore). 2023 Sep 29;102(39):e35094. doi: 10.1097/MD.0000000000035094.
7
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.65 岁及以上、有严重 SARS-CoV-2 感染高风险的美国退伍军人的特征和结局，无论是否接受口服抗病毒药物治疗。
J Infect. 2023 Mar;86(3):248-255. doi: 10.1016/j.jinf.2023.01.018. Epub 2023 Jan 24.
8
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.奥密克戎变异株流行期间奈玛特韦片/利托那韦片与阿兹夫定治疗北京地区 COVID-19 住院患者的真实世界疗效：一项多中心回顾性队列研究。
BMC Infect Dis. 2024 Jan 8;24(1):57. doi: 10.1186/s12879-023-08965-8.
9
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.莫努匹拉韦和奈玛特韦/利托那韦：新型可用的新冠病毒抗病毒药物选择
Acta Med Indones. 2022 Oct;54(4):638-644.
10
Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.阿兹夫定与奈玛特韦-利托那韦治疗住院COVID-19患者的真实世界有效性：一项回顾性队列研究。
J Med Virol. 2023 Apr;95(4):e28756. doi: 10.1002/jmv.28756.

引用本文的文献

1
Time to antiviral treatment in mild-moderate COVID-19 in the emergency department: influence of prescribing physician and effect on outcomes.急诊科中轻度至中度新冠肺炎患者开始抗病毒治疗的时间：开处方医生的影响及对治疗结果的作用
Intern Emerg Med. 2025 Apr 21. doi: 10.1007/s11739-025-03927-1.
2
Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions.美国服用其奈玛特韦/利托那韦处方的患者比例。
Infect Dis Ther. 2024 Sep;13(9):2035-2052. doi: 10.1007/s40121-024-01023-z. Epub 2024 Aug 3.